Metaanalysis of the application of Xuebijing injection as an adjuvant in the western routine treatment of severe communityacquired pneumonia
Sun Zhonghua, Xu Chi, Wang Yue, Liu Lijie, Li Bangbang, Liu Xuejuan
2020, 35(10):
869-875.
doi:10.3969/j.issn.1004-583X.2020.10.001
Asbtract
(
398 )
PDF (1371KB)
(
201
)
HTML
Related Articles |
Metrics
Objective To systematically evaluate the efficacy and safety of Xuebijing injection as an adjuvant in the western routine treatment of severe communityacquired pneumonia(SCAP). Methods PubMed, EMBASE, Cochrane Library, CNKI, Wanfang Data, VIP and other databases were searched by computer. The retrieval time was from the establishment of the database to March 2020. According to the set inclusion and exclusion criteria, relevant literature were screened. The methodological quality of the included RCTs was evaluated by the risk bias assessment tool, and the Metadata analysis was performed on the extracted data using Review Manager 5.3 analysis software. Results A total of 9 articles were included, involving a total of 1 410 patients, including 703 in experimental group and 707 in control group. Meta analysis showed that compared with the western routine treatment of SCAP, the application of Xuebijing injection as an adjuvant treatment on the basis of western routine medicine treatment improved the total effective rate (RR=1.29, 95%CI[1.20, 1.38], P<0.01), reduced the leukocyte count (WMD=-3.30, 95%CI[-3.69, -2.91], P<0.01), decrease the level of Creactive protein(WMD=-4.45, 95%CI[-8.16, -0.74], P=0.002), lowered the comprehensive score APACHE Ⅱ (WMD=-0.97, 95%CI[-1.32, - 0.61], P<0.01), lessened mechanical ventilation time (WMD=-87.36, 95%CI[-173.91, -0.80], P=0.05), cut down ICU hospitalization time (WMD=-66.44, 95%CI[-122.38, -10.51], P=0.02). Only 3 articles reported the occurrence of adverse reactions. The results showed that the treatment of SCAP with Xuebijing injection on the basis of the western routine treatment may occur including skin itching, dizziness and headache, diarrhea, upper extremity pain and allergic reactions, with the incidence of 1.6%. Conclusion Treating SCAP with Xuebijing injection can improve the clinical effect, reduce the ICU hospitalization time and improve the quality of life. However, due to the limitations of the included literature in this study, the results of metaanalysis are only for clinical reference.